Aytu Biopharma, Inc. delivered its Form 8-K Current Report to the U.S. Securities and Exchange Commission on February 14, 2022.Aytu BioPharma (Nasdaq: AYTU) has announced business and pipeline progress and reported financial results for its fiscal second quarter 2022 ended December 31, 2021.“The last several months have been a time of significant progress across our…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
